PD3-2-6: Interim safety results from the East/South East (E/SE) Asian subgroup of the open-label TRUST (TaRceva lUng cancer Survival Treatment) study of erlotinib for advanced non-small-cell lung cancer (NSCLC)
2007 ◽
Vol 2
(8)
◽
pp. S464-S465
◽
Keyword(s):
2014 ◽
Vol 12
(4)
◽
pp. 550-559
◽
Keyword(s):
2019 ◽
Vol 146
(1)
◽
pp. 67-74
◽
Keyword(s):
Keyword(s):
2014 ◽
Keyword(s):
Keyword(s):
Keyword(s):
2013 ◽
Vol 109
(8)
◽
pp. 2058-2065
◽
Keyword(s):